PvP Biologics
About PvP Biologics
PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.YEAR FOUNDED:
2015
LEADERSHIP:
Co-founder and CSO: Ingrid Swanson Pultz, Ph.D.
CEO and President: Adam Simpson
Chief Development Officer: Malcolm R. Hill, Pharm.D.
Senior Vice President Manufacturing & Product Development: Mark Mugerditchian
Senior Director, Program Management: Linda Gieschen
CAREER:
Please click here for PvP Biologics' job opportunities.
3 articles about PvP Biologics
-
Three years after Takeda and San Diego-based PvP Biologics inked a $35 million deal to develop a novel treatment for celiac disease, the Japanese pharma company has exercised its option to acquire the company for $330 million.
-
PvP Biologics Announces First-in-Human Clinical Trials for a Novel Therapeutic for Celiac Disease
9/6/2018
Kuma062 is a uniquely engineered, recombinant enzyme that is active under acidic stomach conditions and has high specificity for the parts of gluten that cause the autoimmune reaction leading to celiac disease.
-
PvP Biologics Announces Leadership Team
1/5/2017